Therapy News and Research

RSS

New radiation treatment techniques can reduce risk of neurocognitive adverse effects in children

Children who undergo brain radiation therapy run a significant risk of suffering from permanent neurocognitive adverse effects. These adverse effects are due to the fact that the radiation often encounters healthy tissue. This reduces the formation of new cells, particularly in the hippocampus - the part of the brain involved in memory and learning.

15 Oct 2012

FIGHT HLH Consortium receives EUR 6 million FP7 grant for testing NovImmune's NI-0501

NovImmune SA announced that the European Commission has awarded a 6 million Euros FP7 grant to the "FIGHT HLH" consortium of institutions to support clinical testing of NovImmune's anti-interferon gamma drug candidate, NI-0501.

15 Oct 2012

Regulatory B cells may provide effective treatment for severe autoimmune diseases

Reproducing a rare type of B cell in the laboratory and infusing it back into the body may provide an effective treatment for severe autoimmune diseases such as multiple sclerosis or rheumatoid arthritis, according to researchers at Duke University Medical Center.

15 Oct 2012

Teagasc researchers look to seaweed for proteins with health benefits

Teagasc researchers are looking to seaweed for proteins with health benefits for use as functional foods. Historically, edible seaweeds were consumed by coastal communities across the world and today seaweed is a habitual diet in many countries, particularly in Asia.

15 Oct 2012

Few physicians recommend active surveillance for low-risk prostate cancer

Few physicians recommend active surveillance for low-risk prostate cancer rather than pursuing surgery or radiation, according to a Mayo Clinic study being presented at the North Central Section of the American Urological Association's annual meeting Oct. 10-13 in Chicago.

15 Oct 2012

Pioneering research paves way for new treatments for pulmonary arterial hypertension

Pioneering research conducted by the University of Sheffield is paving the way for new treatments which could benefit patients suffering from the fatal lung disease pulmonary arterial hypertension (PAH).

15 Oct 2012

Scientists take first steps to create neural-like stem cells from muscle tissue

Scientists at Wake Forest Baptist Medical Center have taken the first steps to create neural-like stem cells from muscle tissue in animals.

15 Oct 2012

Scientists resolve new molecular circuit controlling cellular metabolism

Cancer, diabetes, and excess body weight have one thing in common: they alter cellular metabolism. Scientists from the Max Planck Institute of Immunobiology and Epigenetics in Freiburg and the Medical University of Vienna together with an international research team have jointly resolved a new molecular circuit controlling cellular metabolism.

15 Oct 2012

Highlights of Mount Sinai research at Neuroscience 2012

Researchers from Mount Sinai School of Medicine are presenting important discoveries on the involvement of the immune system and dopamine cells in the onset of depression at Neuroscience 2012, the Society for Neuroscience's 42nd annual meeting on October 13 -17 in New Orleans, and are available for interviews.

15 Oct 2012

Elekta Synergy system with Agility 160-leaf MLC now available at Radboud

The first of three newly acquired Elekta Synergy treatment systems equipped with Agility 160-leaf multi-leaf collimator (MLC) is now up and running clinically at Radboud University Nijmegen Medical Center - making the clinic the first in the Netherlands to use Agility.

From Elekta 15 Oct 2012

Treatment of OSA could reduce blood pressure in men with hypertension

A new study suggests that when prescribed by physicians in routine practice and used appropriately by patients, treatment for obstructive sleep apnea (OSA) could reduce blood pressure in men with hypertension.

15 Oct 2012

Genzyme announces key data from AUBAGIO Phase III trial on multiple sclerosis

Genzyme, a Sanofi company announced today that key data from the TOWER trial were presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).

15 Oct 2012

Merck announces results from odanacatib Phase II trial on post-menopausal osteoporosis

Merck, known as MSD outside the United States and Canada, today announced results from a Phase II trial for odanacatib, an investigational cathepsin K (cat-K) inhibitor in development for the treatment of osteoporosis in post-menopausal women.

15 Oct 2012

Researchers identify new genetic signature for sarcoidosis

Researchers at the University of Illinois Hospital & Health Sciences System have identified a genetic signature that distinguishes patients with complicated sarcoidosis, an inflammatory lung disease that can be fatal, from patients with a more benign form of the disease. The gene signature could become the basis for a simple blood test.

15 Oct 2012

Celgene receives FDA approval for ABRAXANE to treat non-small cell lung cancer

Celgene Corporation today announced the U.S. Food and Drug Administration (FDA) has approved ABRAXANE (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) for the first-line treatment of locally advanced or metastatic non-small cell lung cancer, in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy.

15 Oct 2012

FDA expands approved indication for Genentech’s ACTEMRA to treat active rheumatoid arthritis

Genentech, Inc., a member of the Roche Group, today announced that the U.S. Food and Drug Administration (FDA) has expanded the approved indication for ACTEMRA (tocilizumab) for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more disease-modifying antirheumatic drugs (DMARDs).

13 Oct 2012

Curcumin can inhibit formation of prostate cancer metastases

Powdered turmeric has been used for centuries to treat osteoarthritis and other illnesses. Its active ingredient, curcumin, inhibits inflammatory reactions. A new study led by a research team at Ludwig-Maximilians-Universit-t (LMU) in Munich now shows that it can also inhibit formation of metastases.

13 Oct 2012